Small Cell Lung Cancer (SCLC)

Latest News

Factors including age, gender, and facility type may influence the likelihood of pain referrals for lung cancer, suggesting a need for multidisciplinary pain management in this patient population.
Demographic Factors May Impact Pain Management Referrals in SCLC/NSCLC

March 15th 2023

Factors including age, gender, and facility type may influence the likelihood of pain specialist referrals for lung cancer, suggesting a need for multidisciplinary pain management in this patient population.

Investigators indicate that strategies are necessary to identify patients with extensive-stage small cell lung cancer who won’t benefit from immunotherapy-based treatment.
IO/Chemo Associated With Higher Toxicity Risk in ES-SCLC

March 14th 2023

A favorable Glasgow prognostic score appears to correlate with improved overall survival and progression-free survival following treatment with atezolizumab plus carboplatin and etoposide for small cell lung cancer.
Glasgow Prognostic Score May Predict Atezolizumab/Chemo Outcomes in SCLC

February 22nd 2023

Patients 70 years or older with limited stage small cell lung cancer appear to tolerate concurrent thoracic chemoradiotherapy and have similar disease control rates as younger patients.
Concurrent CRT Garners Disease Control, Safety in SCLC Regardless of Age

February 13th 2023

Findings from the phase 1/2 CA001-030 study indicate that BMS-986012 in combination with nivolumab is well tolerated among patients with small cell lung cancer.
BMS-986012 ± Nivolumab Appears Well-Tolerated in Relapsed/Refractory SCLC

January 17th 2023

More News